Scynexis Aces Ibrexafungerp Late-Stage Study To Prevent Vaginal Yeast Infections

Comments
Loading...

Scynexis Inc SCYX has announced results from its Phase 3 CANDLE study of oral ibrexafungerp to prevent recurrent vulvovaginal candidiasis (rVVC), also known as vaginal yeast infection. 

  • The Company plans to submit a supplemental marketing application to prevent rVVC in 1H of 2022 with anticipated approval by the end of the year.
  • The 260-subject study showed that 65.4% of patients receiving ibrexafungerp achieved clinical success by having no recurrence at all through Week 24 compared to 53.1% of placebo-treated patients.
  • Related: Scynexis' Brexafemme For Vaginal Yeast Infections Secures 10 Years Regulatory Exclusivity.
  • The advantage of ibrexafungerp over placebo was sustained over the three-month follow-up period and remained statistically significant.
  • The study also evaluated an additional group of 24 patients who failed to respond to the initial three-day fluconazole regimen and received a one-day open-label treatment course of ibrexafungerp (300 mg BID). 
  • 71% of ibrexafungerp treated patients achieved a significant reduction or elimination of signs and symptoms.
  • Ibrexafungerp is the only fungicidal oral treatment for vaginal yeast infections and received FDA approval in June last year.
  • Price Action: SCYX shares are down 0.77% at $5.13 during the market session on the last check Thursday.
SCYX Logo
SCYXSCYNEXIS Inc
$0.7700-10.3%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum12.23
Growth96.67
Quality-
Value54.29
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: